Quality Assurance of Herbs (Identity and Purity)
Before any herb is purchased, a sample of the
batch being offered for sale is analyzed by
the Quality Control Laboratory and compared
to the quality criteria specified by MediHerb.
At this point, we regularly reject herbs as
only the herbs that meet or exceed the strict
quality criteria are purchased.
When we receive the purchased batch of herb,
it is sampled according to a statistically valid
sampling plan and then subjected to the same
battery of tests as the pre-purchase sample.
Only if the herb passes this second set of
tests is the batch accepted into the factory for
Depending upon the specific herb, the quality assurance process includes testing herbs for:
Over the years, we have found many issues relating to
quality, for example:
- Content of specified actives
- Thin Layer Chromatography fingerprinting
- Microbial levels
- Amount of extraneous matter
- Pesticides and herbicides
- Heavy metals
- Radiation levels
Our stringent testing regimes guard against:
- Substitution of Scutellaria lateriflora (Skullcap) with other Scutellaria spp.
- Replacement of Scutellaria lateriflora (Skullcap) with Teucrium spp. (Germander)
- Adulteration of Hydrastis canadensis (Golden Seal)
- Centella asiatica (Gotu Kola) substituted for Bacopa monnieri (Bacopa)
- Substitution of Stephania tetrandra by Aristolochia spp., which has the potential to cause kidney failure
- Samples of Andrographis paniculata (Andrographis) upon testing at MediHerb, revealed to have no andrographolide content (the active constituent)
- Samples of Vaccinium myrtillus (Bilberry) upon testing at MediHerb, were found to contain a coloring agent, in order to imitate anthocyanins (the quality marker responsible for the blue color in ripe Bilberries). Click Here for Bilberry Adulteration Scientific Poster
- Substitution of species: one herb may be substituted for another less costly herb
- Adulteration of herbs: a high quality and expensive herb may have a cheaper herb or pharmaceutical mixed in with it
- Poor quality of herbs: herbs can vary enormously in quality and this means the effect you and your patients feel can vary enormously
This ensures that the herbs approved for
use in MediHerb products are of the correct
species, are the correct plant part, have the
correct active constituent profile and are free
from contamination. Therefore you as the
clinician can rest assured that the
MediHerb product contains exactly what it
says on the label.
Substitution – Safety
Substitution of Scutellaria lateriflora (Skullcap)
was a prominent issue in 2002 due to an
Australian product being implicated in the
death of a patient. The product contained
Kava and two other herbs, one of these was
meant to be Skullcap. However when the product was
analyzed by the TGA (Australian equivalent of
the FDA) it was found not to contain Skullcap.
For this reason the TGA initiated a safety recall
on this product and other Skullcap products from
that same doctor-only company. In addition
they also recalled other Skullcap products
on the market. This is significant because substitution
of Skullcap with the hepatotoxic herb
Germander (Teucrium spp.) is well known and
has been implicated in cases of liver damage
in the literature. MediHerb became aware of
this problem many years ago and established
stringent quality procedures to ensure that our
Skullcap products would always be authentic.
In his capacity as a member of TMEC
(Traditional Medicines Evaluation Committee)
the forerunner of CMEC (Complementary
Medicines Evaluation Committee), Kerry Bone
alerted the TGA to the potential harm that
could arise from this substitution. As a result the TGA took action in the 1990s to ensure
that manufacturers only used authentic
Skullcap. They conducted widespread testing
of Skullcap products and found many products
did not contain Skullcap as claimed. The fact
that this substitution may have arisen again,
particularly in the context of the case of liver
damage, is cause for serious concern.
The substitution of Stephania tetrandra with Aristolochia spp. has been widespread in the
herbal market with safety alerts being issued
by the FDA, TGA (Australia) and MHRA (England).
This followed the more than 70 cases of renal
failure in Belgium associated with a weight-loss
product that mistakenly contained a
species of Aristolochia instead of Stephania.
This inadvertent substitution is believed
to have been due to the similarity of the
Chinese common name: Aristolochia fangchi (Guang Fang Ji) and Stephania tetrandra (Fang Ji). Stephania is an important herb with good anti-inflammatory activity, linked to the bisbenzylisoquinoline alkaloid known as tetrandrine. MediHerb research evaluated by HPLC eight samples of herb labelled as Stephania tetrandra. Of these samples only one was believed to be Stephania; five samples contained aristolochic acids and were more likely to be Aristolochia; the remaining two samples contained neither aristolochic acids or tetrandrine, and were probably either Clematis spp. or Akebia spp. Based on this survey, the risk involved in the commercially available Stephania herb was evaluated as being too high to warrant its inclusion in the product line.
Substitution – Efficacy
Through our research we have demonstrated that the alkylamide rich roots of Echinacea angustifolia and to a lesser extent E. purpurea have a modulatory effect on the immune system. However, when market surveillance was performed in October 2004 of eight American professional products of Echinacea tablets and capsules, only one was found to have appropriate levels of alkylamides but even then, the alkylamides were not of the most potent kind (2-ene). The name Echinacea is broadly used to describe all manner of preparations of the Purple Cone Flower plant: different plant parts and different species, but also different quality levels.
Commercial Wild Yam extracts available for
use as raw materials are often not Dioscorea
villosa but instead Dioscorea opposita (Chinese
Yam Root) which has a different phytochemical profile and therefore a different clinical
action. In addition to species substitution, it
is widely misconstrued that Dioscorea villosa
contains diosgenin and many products have
this as a statement on their labels. However
it does not contain diosgenin, but rather the
diosgenin precursors. Traditionally Dioscorea
villosa was believed to contain predominantly
dioscin, however, the origin of this assignment
is unclear (dioscin is a steroidal glycoside
precursor of diosgenin). Research undertaken
by MediHerb and Dr James De Voss from the
University of Queensland, Australia has found
Wild Yam harvested traditionally contains
only very small amounts of dioscin, not the
predominance as previously thought. The major
steroidal glycoside found was a diosgenin based
compound that has an extra sugar molecule
(either glucose or a similar sugar) to that of
dioscin. Further research work continues. It is
alarming that such a widely used herb is so
misunderstood and substituted.
Cat’s Claw (Uncaria tomentosa) has two chemotypes, the preferred chemotype contains only pentacyclic oxindole alkaloids (POAs) speciophylline, mitraphylline, pteropodine, isomitraphylline and isopteropodine; the other chemotype, contains the tetracyclic oxindole alkaloids (TOAs) rhynchophylline and isorhynchophylline in addition to the POAs. Traditionally only the POA chemotype was used therapeutically. This preference for the POA chemotype of Cat’s Claw has been backed up by scientific research. MediHerb tests each batch of Cat’s Claw to determine only the preferred POA chemotype is used to manufacture our Cat’s Claw products.
Golden Seal (Hydrastis canadensis) is very expensive and has always been in short supply. As a result, substitution by other species is common. The herbs typically substituted are: Coptis chinensis, Indian Barberry (Berberis aristata), and Oregon Grape (Berberis aquifolium). These species do not contain hydrastine; they contain only berberine and berberine-related compounds. They do, however, produce an extract of the same color as Golden Seal. The berberine from Golden Seal and the herbs listed above is a potent antibacterial agent. However, it is the hydrastine that is believed responsible for the unique trophorestorative effects of Golden Seal upon mucous membranes. Similarly, the hair roots of Golden Seal, which have lower levels of hydrastine than the rhizome, are sold as the root and rhizome, which provides lower efficacy. The presence of hydrastine and the differentiation of adulterants is easily determined by HPLC. However, many companies
do not have the necessary technology and often
buy herbal ingredients without testing them. MediHerb only purchases cultivated Golden Seal,
due to the report issued by CITES (Convention on
International Trade in Endangered Species of Wild
Fauna and Flora) that the herb is endangered in
its native habitat. This is a very common example
of substitution of a less costly herb which greatly
Substitution – Cost
A very common case of substitution is with
Tribulus due to the high cost of the raw material.
Bulgarian clinical trials utilized a Tribulus extract
characterized at 45% furanosterolic saponins by
UV-Vis spectrometry, with the plant part being
the above ground portion (leaves and stem).
Many Chinese and Indian sources typically specify
the fruit analyzed at 40% by gravimetry – not the
accepted plant part nor analytical method. This
discrepancy is easily overlooked and the price
differential between the two extracts makes
the genuine Bulgarian material economically
unviable for many manufacturers. MediHerb
has extensively investigated Tribulus and has
presented a scientific poster on the comparison
of the spectrophotometric and HPLC-ELSD
analytical methods, highlighting the variability
found in raw herbs of different origins. (Click Here to Download Tribulus Scientific Poster) It was shown that only by HPLC could an accurate
quantification of the true constituents of the herb
be performed. Herbal material from Bulgaria and
Slovakia were the only sources found to have
the same phytochemical profile as the clinically
trialled extract. There was also a significant difference between the phytochemical profile of
the fruit (part used in Asia) compared with the
leaves and stems (clinical trials). Only the leaves
and stems from Tribulus plants of Bulgaria or
Slovakia contain any amount of the active marker
Storage and Handling of Herbs
After approval by the Quality Assurance process,
all herbs are transferred to our refrigerated
warehouse which is maintained at a constant
59°F and 40% humidity. Refrigerated storage,
although expensive to maintain, avoids the
need for any pesticides to be used for insect
control. This ensures our organic herbs remain
organic and ensures that all our herbs remain
free of insect contamination prior to processing.
Herbs are handled and processed at every stage
with the utmost care. For example, herbs are
milled in preparation for extraction under very
low temperature cryogenic conditions to protect
against excessive heating, which can damage the
fragile active components.
Quality of Extraction
MediHerb was co-founded by Kerry Bone,
a first class honors graduate of Melbourne
University who won the Masson Memorial
Prize as Australia’s top Chemistry student.
After eight years as a research scientist, Kerry
then completed, with distinction, the four-year
Diploma in Phytotherapy from the world
renowned School of Phytotherapy in England.
Upon returning to Australia to practice as an
herbalist, he became frustrated with the poor
quality of herbal extracts available at that time
and the resulting effects for his patients. By
applying his scientific training he developed a
unique method of extraction, termed 1:2 Cold
Percolation. Word of these high quality herbal
products spread and requests were soon received
from health care professionals for supply around
Australia and so MediHerb was born.
MediHerb is the first choice in herbal products
for Australian health care professionals and since
2001 MediHerb has been available in the United
States through our partnership with Standard
Process Inc.® Both companies share the same
philosophy and unwavering commitment to
product quality and excellent service.
Unique Extraction: 1:2 Cold Percolation Process
The 1:2 Cold Percolation method is unlike other herbal extraction processes; no heat or concentration are used, both of which may cause damage to the delicate plant material. The greatest care is taken to prevent any contamination from outside sources throughout the extraction process:
- All extraction equipment is designed and built from
- Air used in the manufacturing complex is thoroughly
cleansed using pharmaceutical standard filtering units
MediHerb prefers to use high quality dried herbs
in making extracts rather than fresh herbs. Fresh
herbs have a high water content, up to 80% and
this makes for a weaker extract. In addition to the herb itself, we use only two other raw materials in manufacturing our herbal extracts, ethanol and purified water. Both are chosen very carefully to ensure the most efficacious product and meet pharmaceutical standard specifications.
All process water used in extraction is purified by reverse osmosis. First, it is filtered through numerous filter beds to remove particulate matter and organic compounds, then passed through reverse osmosis cartridges to remove the ionic materials before finally passing through an ultra-fine filter. The water produced is very low in all contaminants – organic, ionic and particulate – and is tested to comply with the British Pharmacopoeia specification for purified water BP2004.
MediHerb only uses ethanol that complies with the British Pharmacopoeia specification for ethanol, BP2004. Ethanol is essential to extract the full phytochemical profile of the plant, this cannot be achieved using water or glycerol alone. Ethanol has been used for hundreds of years in herbal extraction and old herbal texts discuss steeping herbs in wine over long periods. The human liver is naturally conditioned to metabolize small amounts of ethanol from ripe fruit and naturally fermented food. Any toxic effects from ethanol are dose-related and there is minimal risk of potential ethanol toxicity with herbal extracts due to the low daily dosage required. The usual recommended dose of most 1:2 herbal extracts is only 5 mL three times per day and in 5 mL there is approximately the same amount of ethanol as 1/6 of a standard glass of beer or wine.
Through our scientific analysis MediHerb has
chosen specific ethanol percentages for each
herb to maximize the quality, for example 25%
ethanol extracts of Milk Thistle will not contain
any silymarin because it is insoluble at this
Quality Guaranteed – The MediHerb "Quantified Activity" Program
The MediHerb Quantified Activity (QA) program
aims to establish meaningful quality guidelines
for the manufacture of herbal extracts. It is a
system for ensuring the production of consistent
quality extracts with guaranteed minimum levels
of active constituents.
To date, MediHerb has quantified the activity
of over 70 herbs through this program. To our
knowledge such a program has never been
undertaken in Australia, nor has it been matched
anywhere in the world.
The constituents chosen as ‘quality indicators’ are
carefully selected under the guidance of Kerry
Bone and represent the most up-to-date scientific
The process of developing Quantified Activity
extracts is complex and involves many steps.
However, once the constituents are selected
and the quantified activity levels are set, the
main focus is to ensure the supply of consistent
quality raw material and the retention of the
constituents throughout the manufacturing
It is important to point out that Quantified Activity
extracts are not purified single constituent
extracts nor have they been manipulated in any
way by non-traditional processes. They are whole
galenical extracts of carefully selected whole
herbs, manufactured using the MediHerb 1:2 Cold
Percolation process, and still contain the complex
range of active constituents from the raw herb.
In other words, quantified activity extracts are
mainly achieved by the testing and selection
of high quality, carefully dried raw materials.
The Echinacea QA Story
Echinacea is MediHerb’s first quality story and a
good example to explain the Quantified Activity
When MediHerb first started manufacturing
in 1986 there was confusion in the global herbal industry over what constituted authentic
Echinacea. Echinacea angustifolia and E. purpurea
were routinely being substituted by unsuspecting
manufacturers with another herb, Parthenium
integrifolium. The substitution was made possible
due to the uncanny physical similarity of the
roots of Parthenium and especially
The solution implemented by MediHerb to guarantee supply of authentic Echinacea led to the development of the “Quantified Activity” program which exposed the Parthenium/Echinacea substitution and helped establish MediHerb’s credibility in the herbal industry.
The earliest methods employed by MediHerb to assess herb quality and identity relied on a trained herbalist checking the herb’s physical appearance, color, odor and taste. Taste was of particular importance because of the insight it gave into the herb’s chemistry.
Traditionally, the test for Echinacea quality was the ability of the root to cause an intense tingling sensation in the mouth when chewed. The substitution of Parthenium integrifolium for Echinacea was successful only if appearance was checked and taste was not. When chewed, Parthenium root did not cause any tingling sensation in the mouth. The components which cause the tingling sensation from Echinacea are called alkylamides. So, one very simple solution was to taste the roots!
As MediHerb developed more sophisticated analyses, thin layer chromatography (TLC) was adopted which allowed the gross aspects of Echinacea’s chemistry or its “chemical fingerprint” to be compared to a certified reference sample from the correct species. However, TLC mainly demonstrates if a compound is present, but not its quantity.
MediHerb understood that alkylamides were important for the efficacy of Echinacea and began to investigate methods to quantify the alkylamides along with other important compounds such as cichoric acid. At the time there was no published test methodology for alkylamides and the process of developing the high pressure liquid chromatography (HPLC) methodology took MediHerb a number of years.
Once armed with the HPLC methodology for identifying quality in terms of alkylamide content, MediHerb worked with Echinacea growers to determine appropriate growing conditions and handling parameters to ensure optimum retention of the alkylamides. Internally, MediHerb established protocols to ensure optimum retention and stability of alkylamides during all phases of the production process; from receipt of the raw material to completion of the finished product. Alkylamides are very delicate compounds and are easily damaged or lost during processing, hence developing these protocols took many years to conclude.
From these exacting analyses MediHerb was able to establish our standard for acceptance of Echinacea raw material based on alkylamide content. The task then was to work with herb growers to ensure that we were able to consistently source the herb according to our specification. Using our validated 1:2 Cold Percolation process we could then be confident that we would always extract a known amount of alkylamides along with all the other active compounds in every batch. Thus ensuring a consistent quality product with “Quantified Activity”, every batch, every time.
The research into Echinacea continues today and our most recent efforts are aimed at further improving quality and efficacy, and understanding how Echinacea works. (Click here for further information on this ground-breaking research.)
Quantified Activity and Standardization
At times, we receive an herb that has higher levels than our minimum specification, so you as the clinician receive that higher level of activity. We never dilute to meet a minimum specification. Herein lies the difference between Quantified Activity and standardization. With standardization, extracts with an active level that exceeds the specified standard would then be diluted to fall within that standard.
With the MediHerb Quantified Activity program, we have linked together all of the possible parameters that can affect product and extract quality and can guarantee that a high quality, efficacious extract will be produced every time.
Standardized Extracts: A Balanced Perspective
In those cases where there are strong clinical
data supporting the use of a particular
standardized extract, MediHerb has adopted
that standard and dosage approach for its tablet
products. A good example is Ginkgo biloba.
There is considerable controversy and
misinformation over the use of standardized
extracts. Many of these are in fact full spectrum
galencial extracts, made by traditional extraction
with ethanol and water, which are merely
produced to a consistent quality marker (or
markers). No adulteration of the extract has
taken place and isolated phytochemicals have
not been added to the extract. Good examples
of these are Devil’s Claw, St John’s Wort and
Horsechestnut. In addition, MediHerb’s extensive
quality control procedures are capable of
detecting adulterated or “spiked” extracts. Such
extracts are never used in MediHerb products.
For more information on this complex topic see
Kerry Bone’s articles (Modern Phytotherapist Vol 6, No 1 & 2).
Phytoequivalence is a concept that was
developed in Germany in the mid-1990s,
and means that one herbal extract matches,
or is equivalent to, another herbal extract,
more specifically one of the clinically-proven
extracts. It is somewhat of a misnomer as
phytoequivalence really means chemical
equivalence, ie that the two extracts have the
same chemical profile. But it was also intended
to mean more than that. Extracts that are
phytoequivalent should be able to demonstrate
the same pharmacological or physiological
activity when ingested by humans. This is
however difficult to demonstrate (for example,
it could be done by showing the similarity
of the levels of marker compounds (or their
derivatives) in the bloodstream of humans
after oral doses of the two products). A marker
compound is a characteristic compound used to
represent the quality standard for a standardized
extract – it is often, but, not necessarily, one of
the pharmacologically active compounds.
At the very least a match of the chemical profile,
such as a chromatographic fingerprint, which
outlines the full chemical spectrum of the extract
is required. Comparison with the reference
(clinically-proven) extract should indicate the
presence of all major constituents, and the
same levels of marker compounds and similar levels of all other measurable constituents. It
is important to realize that phytoequivalence is
not demonstrated by just comparing the level of
only one or two marker compounds.
Obtaining a good chromatographic fingerprint
(usually by high performance liquid
chromatography (HPLC)) for investigating
phytoequivalence for an herb depends on
- A good extraction method to obtain almost
all the pharmaceutically active compounds
- A chromatogram with good separation
- A representative concentration profile of the
bioactive components detected by a proper
Bulgarian clinical trials have shown that Tribulus
leaf extract rich in protodioscin enhances
libido and fertility and alleviates menopausal
symptoms. If a Tribulus product is made from
the root or fruit of the plant, or is sourced from
anywhere else other than Eastern Europe, it
will probably contain low levels of protodioscin
and so will be quite different to the clinically-proven
Bulgarian standardized extract. This is
despite what might be claimed on the label for
such products because often inferior methods
of analysis have been used to measure the
furostanol saponins (which includes the marker
compound, protodioscin), such as gravimetric or
colorimetric techniques. The phytoequivalence
and quality of Tribulus products is best assessed
In a paper published in 2004, researchers from
China compared 18 fingerprints of Ginkgo biloba
extracts purchased from pharmaceutical stores,
companies and collected from producing areas
of China. All of these samples were supposed
to meet the standard for flavonoids measured by ultraviolet spectroscopy. Standardized extract
of Ginkgo from Europe was the clinically-proven
extract used as the reference for
phytoequivalence. The samples looked similar
in the HPLC chromatograms, however further
statistical analysis of this data indicated problems
with three samples. A peak in two samples
around the retention time of 10 minutes was
much higher than the peak in the standardized
Ginkgo extract, and was found to be the flavonoid
rutin which had been added (in order to meet the
old, UV spectroscopy standard). Inferior clinical
results might well have been obtained using
these non-phytoequivalent extracts.
MediHerb goes to great lengths using
sophisticated analytical methodology to ensure
that products such as Ginkgo 2:1 standardized
liquid extract, Ginkgo 2000mg tablets, Tribulus
tablets and Saligesic tablets are phytoequivalent
to the clinically trialed products.
Quality in Tableting "The MediHerb Way"
In recent times tablets have established a vital
role in modern phytotherapy. Provided they retain
the full potency of the galenicals, they represent a
patient-friendly form of therapy which can vastly
enhance compliance. Many experienced clinicians
who are MediHerb customers rely on our tablet
range for poorly-compliant patients and also to
treat difficult or complex cases where just a liquid
formulation may not be sufficient treatment on its
own. In addition several herbs are best given in
tablet form in order to conveniently achieve the
necessary effective dose (as established in clinical
trials eg Tribulus) or to avoid excessive amounts of
ethanol (eg Boswellia).
We have a different way to make tablets – which
is why we call it the MediHerb way. So what do
we do that is different?
Firstly and perhaps most importantly, our unique
cold percolation 1:2 liquid extracts are used in the
manufacture of the MediHerb tablet range which
means they are very potent and equivalent to the
original galenical liquid extract. Many other herbal
tablets/capsules are made from powdered dried
herbs or poor quality dried extracts which means
they are far less potent or potentially adulterated.
Secondly, our tablet production process has been the focus of extensive research and development to ensure that the finished tablet is as efficacious as the liquid extract, and that the full phytochemical profile has been retained.
From our research, we have found that the optimal method of herb processing involves the evaporation of the ethanol and water at low temperatures under vacuum. This important step minimizes the exposure of the delicate chemicals in the herbal matrix to the damaging effects of heat and oxidation.
The MediHerb tableting process takes this one step further to actually specify the optimal parameters employed during the evaporation and drying processes for each of the active constituents of the final tablet.
While the MediHerb cold percolation 1:2 liquid extracts are used for manufacturing our tablet range, there are on occasion some high quality extracts available from specialist extract manufacturers. In this case, we still apply the MediHerb stringent quality analysis at every step of the purchasing and manufacturing process to ensure our product is of superior quality. For example, there are many St John’s Wort extracts available for purchase but of varying quality. MediHerb would only consider purchasing an extract if it exceeded our quality standards.
As with the MediHerb liquid herbal extracts, our tablets are manufactured to pharmaceutical standards. Each batch of tablets is tested for disintegration, friability, weight uniformity, and where relevant, for active constituents. However, it is only by ongoing research and control of all stages of the manufacturing process from RAW HERB / EXTRACT > LIQUID > TABLET that MediHerb has been able to produce superior tablet formulations, producing tablets with high active constituents that still comply to pharmaceutical standards.
MediHerb tablets must legally disintegrate in less than 30 minutes. This means that even patients with poor digestion can quickly and easily absorb our tablets for maximum efficacy. We believe that
our tablets possess the equivalent bioavailability
of liquids. The bioavailability of key constituents
in our Echinacea Premium tablets has been
verified in a clinical study.
Full Spectrum Extracts Mean Greater Efficacy but Lower Herb Equivalents per Tablet
Health care professionals often compare herb equivalence on tablet labels in an effort to gauge the most effective formula for their patients. However, herb equivalence can be quite misleading when comparing potency of products.
The process of standardization when misused can encourage an approach to manufacturing herbal extracts that only focuses on the one active constituent or marker compound while ignoring the remaining phytochemical profile of the herb. As we know herbs contain a wide variety of phytochemicals in an inert matrix of vegetable matter (eg cellulose). When an herb is extracted with a solvent, the resulting phytochemicals that are extracted will depend upon the type of solvent employed. Generally the insoluble matrix components will be left behind. By using a combination of solvents, one can very selectively extract an individual compound or one group of compounds. However this begs the question as to whether the process produces an herbal product or a product bordering on a pharmaceutical, because the phytochemical profile of the raw herb and the ratio of active constituents to marker compounds can be greatly altered.
One example of this is the use of Scutellaria baicalensis (Chinese Skullcap) extracts, which only contain baicalin and do not contain any of the other 20 or more of its flavonoid constituents. These other constituents are typical of Chinese Skullcap, the most important of these being wogonin-7-O-glucuronide, oroxylin A-7-O-glucuronide, baicalein, wogonin and oroxylin A. Sources of Chinese Skullcap extract used in some herbal tablets contain greater than 95% baicalin, this means that less than 5% of the material is something other than baicalin. This is no longer an herbal extract and is rather a purified phytochemical (refer to the HPLC trace of Chinese Skullcap and baicalin below). These extracts are typically claimed to be a 20:1 dry extract and as such 500 mg of this extract placed into a tablet means the manufacturer or marketer of the product would be able to claim (20 x 500 mg) 10,000 mg of Scutellaria baicalensis dry root.
In contrast, the extract produced by extraction of Chinese Skullcap with 45% ethanol contains a very high level of solids material and a full complement of the many flavonoid components. As a result, a dry extract made from this liquid can only be manufactured with a 3:1 dry extract concentration factor. Adding 500 mg of this MediHerb extract into a tablet means we can only claim (3 x 500 mg) 1500 mg of Scutellaria baicalensis dry root.